TRVI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Today's Volume	78 994.00
Average Volume	222 885
Market Cap	181.02M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.110 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.56
ATR14	$0.0100 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-29	Sciascia Thomas	Buy	59 354	Common Stock
2024-05-29	Sciascia Thomas	Sell	53 368	Common Stock
2024-05-29	Sciascia Thomas	Sell	59 354	Stock Option (right to buy)
2024-05-22	Delfini Lisa	Buy	16 043	Common Stock
2024-05-22	Delfini Lisa	Sell	4 350	Common Stock

INSIDER POWER
67.19
Last 98 transactions
Buy: 4 063 344 \| Sell: 1 571 380

Volume Correlation

Long: -0.03 (neutral)

Short: 0.37 (neutral)

Signal:(54.367) Neutral

Trevi Therapeutics Inc Correlation

10 Most Positive Correlations
ADSE	0.94
MEDP	0.937
AIHS	0.934
MOR	0.934
SPBC	0.933
SMCI	0.933
RTH	0.932
PDP	0.926
NVDA	0.925
CLBT	0.925

10 Most Negative Correlations
CYAN	-0.95
WTER	-0.943
SSRM	-0.942
BIOL	-0.94
WISA	-0.938
SABR	-0.928
FINW	-0.927
ALNY	-0.926
UTMD	-0.923
LTRX	-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevi Therapeutics Inc Correlation - Currency/Commodity

-0.78
( moderate negative )

-0.67
( moderate negative )

0.00
( neutral )

-0.69
( moderate negative )

0.67
( moderate )

Trevi Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Revenue:	$0
Gross Profit:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Revenue:	$0
Gross Profit:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.